[사회]NovaVax Vaccine ‘Technology Transfer’ First Case … “Stable Supply Base”

[앵커]

It is also important that NovaVax’s COVID-19 vaccine produces 20 million people in Korea, but it is significant because the technology transfer method was applied for the first time.

It is assessed to have established a stable supply base amid fierce competition for vaccines around the world.

Reporter Park Hong-gu about the report.

[기자]

NovaVax, which had been discussing plans to introduce a COVID-19 vaccine with the Korean government a month ago, signed a purchase contract.

SK Bioscience, a national manufacturer, decided to produce 20 million people in its national factory and signed a technology transfer contract.

SK explained that the meaning of the technology transfer is to have the right to independently use NovaVax’s vaccine production technology in Korea, rather than simply production on consignment.

This means that if more vaccines are needed, additional vaccines can be produced and sold at their own discretion without approval from NovaVax headquarters.

[양동교 / 질병관리청 자원관리반장 : SK바이오사이언스에서 공급과 생산에 대한 권한을 함께 가지기 때문에 보다 안정적으로 우리나라에 백신공급이 가능해졌다고 평가할 수 있겠습니다.]

The NovaVax vaccine is a synthetic antigen method that is applied to existing hepatitis B vaccines, and the method of inducing immunity is different from the government-purchased Pfizer and AstraZenekawa.

Phase 3 clinical trials are currently in progress in the United States and other countries, and we plan to apply for an emergency license from the US Food and Drug Administration and the FDA soon.

[정기석 / 한림대성심병원 호흡기내과 교수 : 예방효과가 90% 안팎을 넘나들 정도로 굉장히 좋고요. 스파이크 단백질이라는 단백질하고 가장 유사하게 생긴 것 자체를 집어넣어주는 겁니다.]

When the introduction of 20 million supplies of NovaVax was confirmed amid global competition to secure vaccines, the government’s vaccination plan was impressive.

NovaVax will receive approval from the Ministry of Food and Drug Safety when the results of the phase 3 clinical trials are published, and then the specific targets for vaccination will be determined through discussions with the committee of vaccination specialists.

This is YTN Park Hong-gu.

※ ‘Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]